Bexarotene

Use

Bexarotene was launched in the US for the treatment of manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. The four step synthesis of bexarotene involves a double Friedel-Craft alkylation of toluene with 2,5-dichloro-2,5-dimethylhexane followed by acylation with monomethylterephthalic acid chloride, then Wittig methylidenation. Bexarotene is the first retinoid X receptor (RXR) agonist to be selective versus retinoid A receptors (RAR). Its activation of the three RXRα, β, γ isoforms induces cell differentiation and apoptosis and inhibits cell proliferation in several models of cancer. In phase ll/lll clinical trials, 48% of patients with refractory or persistent early-stage cutaneous T-cell lymphoma achieved a complete or partial response when treated with 300 mg/m2/day of bexarotene. It was shown in phase I trials that this second-generation retinoid was substantially less toxic than the broad-spectrum or RARselective retinoids.

Bexarotene manufacturers

• Bexarotene
• 
• 2025-05-21
• CAS:153559-49-0
• Min. Order:
• Purity: 0.99
• Supply Ability:

• Bexarotene
• 
• US $0.00 / KG
• 2025-05-16
• CAS:153559-49-0
• Min. Order: 1KG
• Purity: 99%
• Supply Ability: 50000KG/month

• Bexarotene
• 
• US $10.00 / KG
• 2025-04-23
• CAS:153559-49-0
• Min. Order: 100KG
• Purity: 99%
• Supply Ability: 100 mt